The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
作者： Hiroki Nishikawa , Eriko Iguchi , Yorimitsu Koshikawa , Soichiro Ako , Tadashi Inuzuka
关键词: Ribavirin 、 Hepacivirus 、 Alpha interferon 、 Hepatocellular carcinoma 、 Internal medicine 、 Pegylated interferon 、 Gastroenterology 、 Viral load 、 Immunology 、 Medicine 、 Combination therapy 、 Hepatitis C virus
摘要: Background The clearance of hepatitis C virus infection by interferon therapy significantly reduces the incidence hepatocellular carcinoma and death in elderly chronic patients. However, there are few reports concerning efficacy safety pegylated interferon-alpha2b plus ribavirin combination The aims present study were to examine effect 427 patients with infection. We compared rates sustained virological response--defined as absence detectable serum 24 weeks after treatment ended--and discontinuation rate between 319 younger aged < 65 years 108 ≥ years. also examined factors contributing a response.
biomedcentral.com
springer.com
core.ac.uk
elsevier.com
doaj.org参考文章(27)
Annarosa Floreani, Eliseo Minola, Isabella Carderi, Francesco Ferrara, Erik Rosa Rizzotto, Vincenzo Baldo, Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C Journal of the American Geriatrics Society. ,vol. 54, pp. 549- 550 ,(2006) , 10.1111/J.1532-5415.2006.00643_4.X
Hans Popper, American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury Gastroenterology. ,vol. 38, pp. 786- 804 ,(1960) , 10.1016/S0016-5085(60)80094-7
John G McHutchison, Michael Manns, Keyur Patel, Thierry Poynard, Karen L Lindsay, Christian Trepo, Jules Dienstag, William M Lee, Carmen Mak, Jean–Jacques Garaud, Janice K Albrecht, International Hepatitis Interventional Therapy Group, Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology. ,vol. 123, pp. 1061- 1069 ,(2002) , 10.1053/GAST.2002.35950
Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Rikako Koyama, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada, Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. ,vol. 50, pp. 16- 23 ,(2007) , 10.1159/000096308
Edoardo G. Giannini, Monica Basso, Vincenzo Savarino, Antonino Picciotto, Predictive Factors for Response to Peginterferon-Alpha and Ribavirin Treatment of Chronic HCV Infection in Patients Aged 65 Years and More Digestive Diseases and Sciences. ,vol. 55, pp. 3193- 3199 ,(2010) , 10.1007/S10620-010-1408-X
Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Kaytayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi, Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy Journal of Hepatology. ,vol. 54, pp. 604- 611 ,(2011) , 10.1016/J.JHEP.2010.07.043
Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yuzo Miyakawa, Hiromitsu Kumada, Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Digestive Diseases and Sciences. ,vol. 54, pp. 1317- 1324 ,(2009) , 10.1007/S10620-008-0500-Y
Takashi Honda, Yoshiaki Katano, Junichi Shimizu, Yoji Ishizu, Masao Doizaki, Kazuhiko Hayashi, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Fumihiro Urano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto, Efficacy of peginterferon‐α‐2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C Liver International. ,vol. 30, pp. 527- 537 ,(2010) , 10.1111/J.1478-3231.2009.02064.X
T. Oze, N. Hiramatsu, T. Yakushijin, M. Kurokawa, T. Igura, K. Mochizuki, K. Imanaka, A. Yamada, M. Oshita, H. Hagiwara, E. Mita, T. Ito, Y. Inui, T. Hijioka, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin Journal of Viral Hepatitis. ,vol. 16, pp. 578- 585 ,(2009) , 10.1111/J.1365-2893.2009.01116.X
Hisayuki Hamada, Hiroshi Yatsuhashi, Koji Yano, Manabu Daikoku, Kokichi Arisawa, Osami Inoue, Michiaki Koga, Keisuke Nakata, Katsumi Eguchi, Michitami Yano, Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C Cancer. ,vol. 95, pp. 331- 339 ,(2002) , 10.1002/CNCR.10662